Genocea Biosciences Inc. buy stratec
Summary
This prediction ended on 06.09.18 with a price of €4.33. The BUY prediction by stratec for Genocea Biosciences Inc. performed very badly with a performance of -51.60%. stratec has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -0.552% | 3.281% | 15.052% | 17.017% |
iShares Nasdaq 100 | -1.415% | 4.535% | 26.243% | 54.337% |
iShares Nikkei 225® | -0.877% | -1.739% | 4.897% | 4.751% |
iShares S&P 500 | -0.415% | 3.239% | 23.253% | 46.758% |
Comments by stratec for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Genocea : Cantor sees five-bagger potential
Cantor Fitzgerald set a Street-high price target of $5, suggesting a near-quintupling from today's close of $1.03.